Applied Molecular Transport Inc. - AMTI STOCK NEWS

Applied Molecular Transport Inc. (AMTI) has successfully closed its underwritten public offering of 2,875,000 shares of common stock, including an additional 375,000 shares purchased by underwriters, at $42.00 each. This offering raised approximately $120.8 million in gross proceeds before expenses. The offering was managed by BofA Securities, Jefferies, and SVB Leerink. The registration statement for these securities became effective on March 31, 2021.

Applied Molecular Transport (AMTI) has announced a public offering of 2,500,000 shares of its common stock at $42.00 each, aiming to raise approximately $105 million before expenses. The underwriters, including BofA Securities, Jefferies, and SVB Leerink, have a 30-day option to purchase an additional 375,000 shares at the same price. The offering is anticipated to close on April 6, 2021, contingent upon customary closing conditions. The shares are being offered solely by AMTI, and this move is expected to bolster its financial position amid ongoing clinical developments.

Applied Molecular Transport Inc. (Nasdaq: AMTI) announced a public offering of 2,500,000 shares of its common stock, all to be sold by the company. The offering includes a 30-day option for underwriters to purchase an additional 375,000 shares. The offering is subject to market conditions and other factors. BofA Securities, Jefferies, and SVB Leerink are the book-running managers for the offering. A registration statement has been filed with the SEC but is not yet effective, and no securities can be sold beforehand.

Applied Molecular Transport Inc. (AMTI) announced the appointment of Earl Douglas as General Counsel, enhancing its executive leadership amid critical timelines for clinical trials. Douglas, with over 30 years of experience, will lead all legal activities and support the advancement of their pipeline, including the upcoming release of top-line data for AMT-101 from four Phase 2 trials in the latter half of 2021. The company also continues to develop AMT-126, with the first subject dosed in Phase 1a trial earlier this year.

Applied Molecular Transport Inc. (Nasdaq: AMTI) reported a successful initiation of four Phase 2 trials for oral AMT-101, targeting ulcerative colitis and rheumatoid arthritis, with topline data expected in late 2021 and early 2022. The company also introduced a new candidate, AMT-126, an oral IL-22 biologic, currently in Phase 1a trials. Financially, 2020 saw R&D expenses rise to $53.9 million from $24.3 million in 2019, and G&A expenses increased to $12.7 million. The net loss for 2020 was $66.6 million, compared to $28.0 million in the previous year, while cash reserves stood at $129.9 million.

Applied Molecular Transport Inc. (Nasdaq: AMTI) will feature CEO Tahir Mahmood in a fireside chat at the Oppenheimer 31st Annual Healthcare Conference on March 18, 2021, at 11:20 a.m. ET. The event will provide insights into AMT's innovative approaches in developing oral biologic products targeting autoimmune and inflammatory diseases. A live webcast will be available on the company's events page, with a replay for 30 days post-event. AMT’s technology enables enhanced transport across the intestinal barrier, marking a significant advancement in biopharmaceutical design.

Applied Molecular Transport Inc. (AMTI) announced the first human dosing of oral AMT-126 in a Phase 1a clinical trial targeting gastrointestinal diseases related to intestinal epithelial barrier defects. The trial involves up to 50 healthy volunteers to assess safety and tolerability. AMT-126, an oral IL-22 fusion biologic, aims to enhance gut health by repairing epithelial barriers. Concurrently, AMTI is set to release top-line data for AMT-101 in four Phase 2 trials later this year, indicating progress in their clinical pipeline.

Applied Molecular Transport Inc. (Nasdaq: AMTI) announced that CEO Tahir Mahmood will participate in a fireside chat at the SVB Leerink 10th Annual Global Healthcare Conference on February 25, 2021, at 4:20 p.m. ET. A live webcast will be available on the company's website, with an archived replay accessible for 30 days post-event.

AMTI is a clinical-stage biopharmaceutical firm focused on developing novel oral biologics for autoimmune and inflammatory diseases using a proprietary technology platform.

Applied Molecular Transport Inc. (Nasdaq: AMTI) has appointed Douglas Rich as Chief Technical Officer, aiming to enhance GMP manufacturing and formulation development. He brings over 26 years of biopharma experience, with previous roles at UNITY Biotechnology and Amgen. This leadership change comes as the company advances its pipeline, initiating two Phase 2 trials for oral AMT-101 targeting pouchitis and rheumatoid arthritis. CEO Tahir Mahmood emphasizes Rich's expertise as key to AMT's growth strategy and ongoing clinical progress.